The correlation of IL28B genotype with sustained virologic response in Romanian patients with chronic hepatitis C

Hepatitis Monthly

Volumn 11, Issue 12, 2011, Pages 975-979

  Sporea, Ioan ^a   Popescu, Alina ^a   Curescu, Manuela ^a   Sirli, Roxana ^a   Dan, Isabel ^a   Goldis, Adrian ^a   Gradinaru, Oana ^a   Ardelean, Melania ^a   Danila, Mirela ^a   Bota, Simona ^a   Deleanu, Alexandra ^a  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Chronic; Genetic Variation; Human Hepatitis C; IL28B Protein

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; BODY MASS; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEPATITIS C; HUMAN; IL28B GENE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; ROMANIA; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; VIRUS LOAD;

EID: 84855757818     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/kowsar.1735143X.4202     Document Type: Article

References (21)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5(9):558-67.
2. World Health organization. Hepatits C. Fact sheet n°164. WHo; 2009 [updated 2011 June]; Available from: www.who.int/mediacen-tre/factsheets/fs164/en/.
3. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361(6):580-93.
4. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2009;358(9286):958-65.
5. Sporea I, Sirli R, Curescu M, Gheorghe L, popescu A, Bota S, et al. outcome of antiviral treatment in patients with chronic geno type 1 HCV hepatitis. A retrospective study in 507 patients. J Gastrointestin Liver Dis. 2010;19(3):261-4.
6. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment induced viral clearance. Nature. 2009;461(7262):399-401.
7. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138(4):1338-45, 45 e1-7.
8. Grebely J, petoumenos K, Hellard M, Matthews GV, Suppiah V, Applegate T, et al. potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology. 2010;52(4):1216-24.
9. Grigorescu M. HCV genotype 1 is almost exclusively present in Romanian patients with chronic hepatitis C. J Gastrointestin Liver Dis. 2009;18(1):45-50.
10. Gheorghe L, Csiki Ie, Iacob S, Gheorghe C, Smira G, Regep L. The prevalence and risk factors of hepatitis C virus infection in adult population in Romania: a nationwide survey 2006 - 2008. J Gastrointestin Liver Dis. 2010;19(4):373-9.
11. French DJ, McDowell DG, Debenham P, Gale N, Brown T. HyBeacon probes for rapid DnA sequence detection and allele discrimination. Methods Mol Biol. 2008;429:171-85.
12. Bossler A, Gunsolly C, Pyne MT, Rendo A, Rachel J, Mills R, et al. performance of the CoBAS(R) Ampliprep/CoBAS TaqMan(R) automated system for hepatitis C virus (HCV) quantification in a multi-center comparison. J Clin Virol. 2011;50(2):100-3.
13. McHutchison JG. The role of genetic markers in hepatitis C virus therapy: a major step for individualized care. Liver Int. 2011;31(Suppl 1):29-35.
14. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41(10):1105-9.
15. Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, et al. pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis. 2008;47(10):1260-9.
16. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139(1):120-9 e18.
17. Sarrazin C, Schwendy S, Moeller B, Dikopoulos N, Buggisch P, Encke J, et al. Completely individualized treatment durations with peginterferon-alfa-2b and ribavirin in HCV genotype 1-infected patients and importance of IL28B genotype (InDIV-2 study). Hepatology. 2010;52(Suppl S1):384A.
18. Stattermayer AF, Stauber R, Hofer H, Rutter K, Beinhardt S, Scher-zer TM, et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2011;9(4):344-50 e2.
19. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology. 2010;139(3):821-7, 7 e1.
20. Kawaoka R, Ochi H, Hiraga N, Tsuge M, Imamura M, Kawakami Y, et al. predictive value of IL-28 polymorphism of effect of interferon therapy in patients with genotype 2a and 2b chronic hepatitis C. Hepatology. 2010;52(Suppl S1):701A.
21. Lagging M, Askarieh G, Negro F, Bibert S, Soderholm J, Westin J, et al. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One. 2011;6(2):e17232.